The drug maker on Saturday said the USFDA has issued a Complete Response Letter (CRL) regarding the new drug application for Ryaltris (olopatadine hydrochloride [665 mcg] and mometasone furoate.
Markets
http://bit.ly/2LgnBvP
Sunday, June 23, 2019
Subscribe to:
Post Comments (Atom)
Hello, my name is Jack Sparrow. I'm a 50 year old self-employed Pirate from the Caribbean.
No comments:
Post a Comment